SOLENO THERAPEUTICS INC

SLNO

SOLENO THERAPEUTICS INC

SLNO

Insider Sentiment (TTM):

Last Purchase:2023-09-28Last Sale:2026-03-27Shares Purchased (TTM):0Shares Sold (TTM):14,104

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:54,043,395Shares Outstanding:52,091,047Institutional Ownership Pct.:103.75%

Earnings Market Reaction:

Filing Date:2026-05-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	133	70	247	76	81	88	48	57	43	170	52	19
Short Term Investments	-	-	-	-	-	-	-	-	107	-	-	-
Marketable Securities Current	123	235	252	210	209	204	208	209	-	-	-	-
Accounts Receivable Net Current	47	28	26	25	-	-	-	-	-	-	-	-
Inventory Net	17	15	7	2	-	-	-	-	-	-	-	-
Prepaid Expense And Other Assets Current	6	7	4	3	19	2	1	1	2	2	1	1
Assets Current	326	356	535	317	309	294	258	268	151	171	54	20
Assets Noncurrent
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	4	2	2	2	3	3	3	0	0	0	0	1
Intangible Assets Net Excluding Goodwill	4	5	5	6	6	7	7	8	8	9	9	10
Long Term Investments	-	-	-	-	-	-	-	-	9	-	-	-
Marketable Securities Noncurrent	273	201	57	7	0	27	28	28	-	-	-	-
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	608	564	600	332	318	331	297	304	169	181	64	31
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	12	12	8	6	5	9	6	4	8	3	3	3
Employee Related Liabilities Current	6	10	7	6	4	5	3	2	1	3	1	1
Operating Lease Liability Current	1	1	1	1	1	1	0	0	0	0	0	0
Interest Payable Current	-	-	-	0	0	-	-	-	-	-	-	-
Asset Acquisition Contingent Consideration Liabili…	14	20	-	-	-	-	-	-	-	-	-	-
Other Liabilities Current	25	18	17	6	3	5	3	1	2	2	1	1
Liabilities Current	58	61	33	21	16	19	15	9	13	12	29	9
Liabilities Noncurrent
Asset Acquisition Contingent Consideration Liabili…	-	-	19	19	18	15	14	14	12	12	10	9
Long Term Debt Noncurrent	50	50	50	50	50	50	-	-	-	-	-	-
Operating Lease Liability Noncurrent	3	2	2	2	2	2	3	0	0	0	0	0
Other Liabilities Noncurrent	1	1	0	0	0	0	-	-	-	-	-	-
Liabilities	113	114	105	92	86	86	32	23	25	23	40	19
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	898	881	969	741	728	697	660	601	441	434	288	267
Accumulated Other Comprehensive Income Loss Net Of…	-2	0	0	0	0	0	1	-0	-0	-	-0	-
Retained Earnings Accumulated Deficit	-400	-431	-475	-501	-496	-452	-396	-320	-298	-276	-265	-254
Stockholders Equity	496	450	495	240	232	245	265	281	143	158	23	12
Liabilities And Stockholders Equity	608	564	600	332	318	331	297	304	169	181	64	31
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	100	100	100	100	100	100	100	100	100	100	100	100
Common Stock Shares Issued	52	52	54	50	49	46	41	38	33	32	15	9
Shares Outstanding	52	52	54	50	49	46	41	38	33	32	15	9

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-	-	-	-	-	-	-	-	-	-	-	-
2025	-1.75%	11.51%	15.82%	-16.65%	-19.99%	-20.95%	-20.99%	-25.37%	-33.66%	-19.03%	28.64%	29.20%
2024	-11.67%	-14.36%	1.76%	11.35%	11.76%	24.93%	-7.30%	-21.17%	-15.48%	0.59%	43.34%	53.65%
2023	37.73%	-0.69%	13.43%	-2.92%	475.24%	338.99%	36.02%	83.54%	112.49%	-4.77%	-15.70%	-8.42%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	5.62	5.80	16.08	15.13	19.64	15.68	17.26	29.24	11.23	14.89	1.85	2.33
Quick Ratio	5.22	5.44	15.77	14.87	18.43	15.55	17.16	29.08	11.11	14.75	1.81	2.20
Working Capital	268.33M	294.45M	501.60M	295.85M	293.18M	275.14M	243.24M	258.35M	137.76M	159.85M	24.67M	11.70M
Leverage & Debt
Debt to Equity	0.23	0.25	0.21	0.38	0.37	0.35	0.12	0.08	0.18	0.15	1.74	1.49
Interest Coverage TTM	15.99	1.72	-21.63	-70.00	-154.25	-	-	-	-	-	-	-
Debt Ratio	0.19	0.20	0.18	0.28	0.27	0.26	0.11	0.08	0.15	0.13	0.63	0.60
Efficiency & Turnover
Asset Turnover TTM	0.62	0.43	0.22	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding TTM	60.37	54.07	94.35	275.22	-	-	-	-	-	-	-	-
Receivables Turnover TTM	6.05	6.75	3.87	1.33	-	-	-	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	1.80	0.39	-1.43	-3.59	-4.29	-4.38	-3.13	-1.69	-1.44	-2.36	-2.90	-2.73
Free Cash Flow Per Share TTM	2.02	0.92	-0.49	-1.67	-1.94	-1.73	-1.23	-1.11	-0.85	-1.51	-2.08	-2.12
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	98.63%	-	-	-	-	-	-	-	-	-	-	-
Operating Profit Margin TTM	30.33%	4.94%	-90.48%	-586.69%	-	-	-	-	-	-	-	-
Net Profit Margin TTM	33.55%	10.75%	-79.50%	-554.49%	-	-	-	-	-	-	-	-
Growth Metrics
Net Income Growth (1Y)	-148.24%	-111.64%	-40.19%	176.84%	280.98%	351.04%	295.33%	129.92%	94.88%	62.00%	54.97%	21.49%
EPS Growth (1Y)	-142.77%	-109.21%	-53.03%	111.85%	198.72%	85.15%	7.96%	-37.96%	-49.15%	-17.52%	27.61%	8.85%
Calculated Values
Free Cash Flow TTM	105.42M	46.73M	-25.92M	-84.49M	-89.53M	-69.31M	-51.63M	-42.84M	-30.75M	-24.94M	-23.78M	-22.11M
Net Debt	-83.16M	-20.24M	-196.81M	-26.65M	-31.50M	-38.10M	-48.41M	-57.02M	-42.85M	-90.00M	-52.44M	-19.37M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-27Sale

Owner: Huang, Michael F.

Title: Sr. VP of Clinical Development

Shares: 6,582

Price/Share: $30.93

Value: $203,581.26

Shares Owned: 39,823

Relationship: Officer

Ownership: Direct

2026-03-27Sale

Owner: Manning, Meredith

Title: Chief Commercial Officer

Shares: 7,522

Price/Share: $30.93

Value: $232,655.46

Shares Owned: 64,507

Relationship: Officer

Ownership: Direct

2025-07-01Sale

Owner: Hirano, Patricia C

Title: SEE REMARKS

Shares: 3,830

Price/Share: $82.76

Value: $316,970.80

Shares Owned: 13,206

Relationship: Officer

Ownership: Direct

2025-06-24Sale

Owner: Hirano, Patricia C

Title: SEE REMARKS

Shares: 266

Price/Share: $84.25

Value: $22,410.50

Shares Owned: 17,036

Relationship: Officer

Ownership: Direct

2025-04-01Sale

Owner: Hirano, Patricia C

Title: SEE REMARKS

Shares: 3,782

Price/Share: $70.11

Value: $265,156.02

Shares Owned: 27,036

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-27	Huang, Michael F.	Officer	Sr. VP of Clinical Development	Direct	Sale	6,582	30.93	$203,581.26	39,823	4
2026-03-27	Manning, Meredith	Officer	Chief Commercial Officer	Direct	Sale	7,522	30.93	$232,655.46	64,507	4
2025-07-01	Hirano, Patricia C	Officer	SEE REMARKS	Direct	Sale	3,830	82.76	$316,970.80	13,206	4
2025-06-24	Hirano, Patricia C	Officer	SEE REMARKS	Direct	Sale	266	84.25	$22,410.50	17,036	4
2025-04-01	Hirano, Patricia C	Officer	SEE REMARKS	Direct	Sale	3,782	70.11	$265,156.02	27,036	4
2025-03-28	Vivo, Opportunity Fund Ho…	TenPercentOwner	-	Indirect	Sale	333,557	70.60	$23,549,124.20	4,458,294	4
2025-03-28	Hirano, Patricia C	Officer	SEE REMARKS	Direct	Sale	27,662	69.88	$1,933,020.56	30,818	4
2025-03-28	Pauls, Matthew	Director	-	Direct	Sale	5,937	71.55	$424,792.35	6,500	4
2025-03-27	Manning, Meredith	Officer	Chief Commercial Officer	Direct	Sale	45,249	69.03	$3,123,538.47	45,351	4
2025-03-27	Mackaness, James H	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	90,622	69.46	$6,294,604.12	105,176	4
2025-03-27	Anish, Bhatnagar	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	699,095	68.58	$47,943,935.10	577,076	4
2025-03-27	Yen, Kristen	Officer	SEE REMARKS	Direct	Sale	95,500	68.72	$6,562,760.00	28,143	4
2025-03-27	Huang, Michael F.	Officer	Sr. VP of Clinical Development	Direct	Sale	14,583	69.36	$1,011,476.88	36,817	4
2025-01-03	Yen, Kristen	Officer	SEE REMARKS	Direct	Sale	2,340	46.18	$108,061.20	76,605	4
2025-01-03	Anish, Bhatnagar	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,154	46.18	$468,911.72	698,462	4
2025-01-03	Hirano, Patricia C	Officer	SEE REMARKS	Direct	Sale	1,459	46.18	$67,376.62	105,902	4
2025-01-03	Mackaness, James H	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,791	46.18	$175,068.38	111,298	4
2024-10-01	Hirano, Patricia C	Officer	SEE REMARKS	Direct	Sale	3,108	49.80	$154,778.40	108,932	4
2024-10-01	Anish, Bhatnagar	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	21,633	49.80	$1,077,323.40	719,553	4
2024-10-01	Mackaness, James H	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	8,077	49.80	$402,234.60	119,172	4
2024-10-01	Yen, Kristen	Officer	SEE REMARKS	Direct	Sale	3,108	49.80	$154,778.40	81,465	4
2024-08-29	Mackaness, James H	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	6,870	47.50	$326,325.00	127,249	4
2024-08-29	Hirano, Patricia C	Officer	SEE REMARKS	Direct	Sale	5,435	47.50	$258,162.50	112,040	4
2024-08-29	Vivo, Opportunity, Llc, V…	TenPercentOwner	-	Indirect	Sale	100,000	47.22	$4,722,000.00	6,291,851	4
2024-08-29	Anish, Bhatnagar	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	58,391	47.50	$2,773,572.50	741,186	4
2024-08-29	Yen, Kristen	Officer	SEE REMARKS	Direct	Sale	5,435	47.50	$258,162.50	84,573	4
2024-08-06	Mackaness, James H	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	8,134	44.93	$365,460.62	140,780	4
2024-08-06	Anish, Bhatnagar	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	69,131	44.93	$3,106,055.83	856,190	4
2024-08-06	Yen, Kristen	Officer	SEE REMARKS	Direct	Sale	5,957	44.93	$267,648.01	95,278	4
2024-08-06	Hirano, Patricia C	Officer	SEE REMARKS	Direct	Sale	5,977	44.93	$268,546.61	122,745	4
2024-07-01	Hirano, Patricia C	Officer	SEE REMARKS	Direct	Sale	2,170	41.42	$89,881.40	48,754	4
2024-07-01	Yen, Kristen	Officer	SEE REMARKS	Direct	Sale	2,170	41.42	$89,881.40	21,252	4
2024-07-01	Anish, Bhatnagar	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	19,256	41.42	$797,583.52	133,534	4
2024-07-01	Mackaness, James H	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	7,190	41.42	$297,809.80	55,763	4
2024-04-30	Vivo, Opportunity Fund Ho…	TenPercentOwner	-	Indirect	Sale	351,242	45.13	$15,851,551.46	7,316,851	4
2024-04-01	Anish, Bhatnagar	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	18,980	41.40	$785,772.00	152,790	4
2024-04-01	Mackaness, James H	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	5,175	41.40	$214,245.00	62,953	4
2024-04-01	Hirano, Patricia C	Officer	SEE REMARKS	Direct	Sale	2,218	41.40	$91,825.20	41,812	4
2024-04-01	Yen, Kristen	Officer	SEE REMARKS	Direct	Sale	2,218	41.40	$91,825.20	23,422	4
2024-01-25	Anish, Bhatnagar	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	2,527	48.30	$122,054.10	171,770	4
2024-01-25	Yen, Kristen	Officer	SEE REMARKS	Direct	Sale	397	48.30	$19,175.10	25,640	4
2024-01-25	Hirano, Patricia C	Officer	SEE REMARKS	Direct	Sale	832	48.30	$40,185.60	43,142	4
2023-12-13	Yen, Kristen	Officer	See Remarks	Direct	Sale	17,916	37.76	$676,508.16	2,037	4
2023-12-13	Hirano, Patricia C	Officer	See Remarks	Direct	Sale	4,885	38.79	$189,489.15	21,333	4
2023-12-11	Mackaness, James H	Officer	Chief Financial Officer	Direct	Sale	32,482	36.24	$1,177,147.68	12,128	4
2023-12-11	Anish, Bhatnagar	Director,Officer	Chief Executive Officer	Direct	Sale	93,408	36.09	$3,371,094.72	24,297	4
2023-11-30	Hirano, Patricia C	Officer	See Remarks	Direct	Sale	3,823	28.65	$109,528.95	26,218	4
2023-11-30	Yen, Kristen	Officer	See Remarks	Direct	Sale	3,963	28.65	$113,539.95	21,950	4
2023-11-30	Mackaness, James H	Officer	Chief Financial Officer	Direct	Sale	4,186	28.65	$119,928.90	21,303	4
2023-11-30	Anish, Bhatnagar	Director,Officer	Chief Executive Officer	Direct	Sale	27,716	28.65	$794,063.40	108,062	4
2023-11-29	Yen, Kristen	Officer	See Remarks	Direct	Sale	3,979	27.84	$110,775.36	25,913	4
2023-11-29	Mackaness, James H	Officer	Chief Financial Officer	Direct	Sale	4,203	27.84	$117,011.52	25,489	4
2023-11-29	Anish, Bhatnagar	Director,Officer	Chief Executive Officer	Direct	Sale	27,827	27.84	$774,703.68	135,778	4
2023-11-28	Hirano, Patricia C	Officer	See Remarks	Direct	Sale	3,542	27.31	$96,732.02	33,880	4
2023-09-28	Perceptive, Advisors Llc,…	TenPercentOwner	-	Indirect	Purchase	250,000	20.00	$5,000,000.00	3,074,542	4
2023-06-02	Perceptive, Advisors Llc,…	TenPercentOwner	-	Indirect	Purchase	64,630	5.93	$383,255.90	2,129,085	4
2023-06-01	Perceptive, Life Sciences…	TenPercentOwner	-	Indirect	Purchase	7,500	5.59	$41,925.00	2,064,455	4
2023-05-26	Edelman, Joseph, Percepti…	TenPercentOwner	-	Indirect	Purchase	22,500	5.27	$118,575.00	2,029,455	4
2023-05-23	Perceptive, Advisors Llc,…	TenPercentOwner	-	Indirect	Purchase	27,500	5.45	$149,875.00	1,944,455	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

103.75%

Inst. Shares: 54,043,395

Shares Outstanding: 52,091,047

2025-12-31

120.72%

Inst. Shares: 61,345,079

Shares Outstanding: 50,817,586

2025-09-30

114.57%

Inst. Shares: 61,095,357

Shares Outstanding: 53,328,094

2025-06-30

104.79%

Inst. Shares: 52,900,128

Shares Outstanding: 50,483,281

2025-03-31

112.49%

Inst. Shares: 51,948,266

Shares Outstanding: 46,178,793

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	54,043,395	52,091,047	103.75%
2025-12-31	61,345,079	50,817,586	120.72%
2025-09-30	61,095,357	53,328,094	114.57%
2025-06-30	52,900,128	50,483,281	104.79%
2025-03-31	51,948,266	46,178,793	112.49%
2024-12-31	49,213,985	40,175,926	122.50%
2024-09-30	45,634,372	41,879,025	108.97%
2024-06-30	42,774,766	38,631,565	110.72%
2024-03-31	34,776,520	36,208,371	96.05%
2023-12-31	31,379,983	16,492,132	190.27%
2023-09-30	20,237,417	11,436,748	176.95%
2023-06-30	4,784,436	10,423,598	45.90%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

SOLENO THERAPEUTICS INC (SLNO) — SEC Financial Statements & Analysis

SOLENO THERAPEUTICS INC (SLNO) is a pharmaceutical preparations company, incorporated in DE. SOLENO THERAPEUTICS INC trades on Nasdaq as: SLNO. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), SOLENO THERAPEUTICS INC reported a Gross Profit Margin of 98.63% (TTM), a Debt-to-Equity ratio of 0.23x. Figures below are sourced from SEC EDGAR, as-filed.

Gross Profit Margin TTM: 98.63%
Debt To Equity: 0.23x

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is SOLENO THERAPEUTICS INC in?

SOLENO THERAPEUTICS INC (SLNO) operates in the Pharmaceutical Preparations industry.

What exchange does SLNO trade on?

SOLENO THERAPEUTICS INC (SLNO) trades on the Nasdaq.

Where is SOLENO THERAPEUTICS INC incorporated?

SOLENO THERAPEUTICS INC is incorporated in DE.